SureTrader SureTrader
Home > Boards > Canadian > Biotechs >

Trillium Therapeutics Inc. (TRIL)

TRIL RSS Feed
Add TRIL Price Alert      Hide Sticky   Hide Intro
Moderator: NY1972
Search This Board:
Last Post: 12/8/2016 1:55:02 PM - Followers: 39 - Board type: Free - Posts Today: 5

Trillium Therapeutics Inc. (NASDAQ:TRIL, TSX:TR)

Home: http://trilliumtherapeutics.com/trillium-home/default.aspx

 

Trillium Therapeutics Inc. 
2488 Dunwin Drive 
Mississauga, Ontario, 
Canada L5L 1J9 
Tel: +1 416.595.0627

 

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase. 

 

SEC filings:  http://www.nasdaq.com/symbol/tril/sec-filings

 

Twitter:  https://twitter.com/search?q=%24TRIL&src=ctag

 

Quote:  https://www.google.com/finance?q=NASDAQ%3ATRIL&ei=dWJkV-kHiKV5wPiX4As

 

Canadian Insider:  https://www.canadianinsider.com/company?menu_tickersearch=tr

 
Currency Converter: http://www.bankofcanada.ca/en/rates/converter.html


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Last update 6/17/2016

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TRIL
Current Price
Volume:
Bid Ask Day's Range
SureTrader
TRIL News: Report of Foreign Issuer (6-k) 12/05/2016 06:05:12 AM
TRIL News: Report of Foreign Issuer (6-k) 11/29/2016 07:03:21 AM
TRIL News: Report of Foreign Issuer (6-k) 11/10/2016 07:06:41 AM
TRIL News: Report of Foreign Issuer (6-k) 11/03/2016 07:10:28 AM
TRIL News: Report of Foreign Issuer (6-k) 11/02/2016 07:02:49 AM
PostSubject
#527   Several retail guys I know where we long ronpopeil 12/08/16 01:55:02 PM
#526   I am retail...have not sold and you indicated DFRAI 12/08/16 01:22:38 PM
#525   Most retail investors have sold out. Not much ronpopeil 12/08/16 01:19:40 PM
#524   Grave dug...just need the patient DFRAI 12/08/16 12:47:50 PM
#523   Grave dug...just need the patient DFRAI 12/08/16 12:47:49 PM
#522   Phase 1a DFRAI 12/05/16 03:54:03 PM
#521   Cowen $TRIL just out -ASH Update: Safety Concerns ronpopeil 12/04/16 09:09:19 PM
#520   Is this the poster they will discuss... dia76ca 12/04/16 07:48:42 PM
#519   An unleashed immune system can attack healthy, vital NY1972 12/04/16 05:43:31 PM
#518   A 'rebuttal' from Dewophile: NY1972 12/04/16 11:10:03 AM
#517   Should have used a "facetious" tag ;) qtmman 12/03/16 11:06:32 PM
#516   Agreed. There was also Impressive preclinical data for ronpopeil 12/03/16 02:17:29 PM
#515   It is a win in the CD47 space. NY1972 12/03/16 02:15:18 PM
#514   What do you think of the data? Is ronpopeil 12/03/16 01:58:52 PM
#513   0.2 mg/kg/week was well-tolerated and associated with predictable, NY1972 12/03/16 01:48:10 PM
#512   Fair and balanced comment from Dewophile: NY1972 12/02/16 04:40:19 PM
#511   No mention on target tox, antigen sink from NY1972 12/02/16 11:49:44 AM
#510   Not surprised, lots traders are running away with NY1972 12/01/16 04:31:12 PM
#509   Surprised at these levels but I understand ronpopeil 12/01/16 03:30:53 PM
#508   Have taken much of my $TRIL position off super_trades 12/01/16 03:25:57 PM
#507   That is a billion $ question. I believe NY1972 12/01/16 03:10:10 PM
#506   $20+ ronpopeil 12/01/16 02:52:12 PM
#505   What would the stock do if TRIL showed gftb5 12/01/16 02:47:42 PM
#504   No but the market doesn't always act rationally ronpopeil 12/01/16 02:43:16 PM
#503   The stock was slammed 50% because of safety NY1972 12/01/16 02:40:53 PM
#502   They need to show some activity or else ronpopeil 12/01/16 02:21:50 PM
#501   I'm adding more as TRIL still has 40 NY1972 12/01/16 02:14:21 PM
#500   At this point I'm holding through the conference. ronpopeil 12/01/16 11:52:31 AM
#499   Fear 100% on TRIL chart, CD47 100% on CSC. NY1972 12/01/16 11:48:39 AM
#498   Pristine cancer treatment from a microcap!! Have you NY1972 11/30/16 02:07:34 PM
#497   Sumting wong. Is it safe to say qtmman 11/30/16 12:57:35 PM
#496   Tril needs to show something in the way ronpopeil 11/29/16 09:21:04 PM
#495   While 47 and CELG still in search of NY1972 11/29/16 09:12:01 PM
#494   It seems like from what I've heard you ronpopeil 11/29/16 07:01:16 PM
#493   Positive according to CMO. The billion $ question NY1972 11/29/16 06:49:20 PM
#492   Do you think it will be a positive ronpopeil 11/29/16 04:17:51 PM
#491   To discuss on target tox and how it NY1972 11/29/16 04:15:55 PM
#490   What do you think the purpose of the ronpopeil 11/29/16 03:57:46 PM
#489   Traders got to thank the CEO. They are NY1972 11/29/16 03:55:20 PM
#488   TRIL http://finance.yahoo.com/news/trillium-therapeutics-announces-conference-ca ronpopeil 11/29/16 07:24:24 AM
#487   Thanks for the advice - i was talking DFRAI 11/28/16 01:36:41 PM
#485   Who buys puts after a drop of 50%? DFRAI 11/28/16 11:19:55 AM
#483   Does anyone think of buying puts? Is DFRAI 11/28/16 10:42:33 AM
#482   18% of patients experienced grade 3 or worse NY1972 11/26/16 06:15:23 PM
#481   Nivolumab in Metastatic Renal Cell Carcinoma NY1972 11/26/16 02:38:23 PM
#480   DLBCL: Expression of PD-L1 is heterogeneous NY1972 11/26/16 02:27:17 PM
#479   severe GVHD with rapid onset and unique complications NY1972 11/26/16 02:11:52 PM
#478   The broad efficacy of TTI-621 across tumor types NY1972 11/24/16 05:17:03 PM
#477   Latest preclinical publication points to why the DLBCL NY1972 11/21/16 09:57:05 PM
#476   http://clincancerres.aacrjournals.org/content/early/2016/11/16/1078-0432.CCR-16- ronpopeil 11/20/16 06:19:54 PM
PostSubject